Homebiopharmaceutical

biopharmaceutical

Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe

Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe

December 19, 2022

ROSEN, A LEADING NATIONAL FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

ROSEN, A LEADING NATIONAL FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 19, 2022

CLASS ACTION UPDATE for SEDG, EIGR and UIS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for SEDG, EIGR and UIS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

December 19, 2022

Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?

Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?

December 19, 2022

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

December 19, 2022

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

December 19, 2022

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

December 19, 2022

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

December 19, 2022

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 17, 2022

EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

December 16, 2022

« 1 … 8 9 10 11 12 … 558 »